CN116966247B - Traditional Chinese medicine composition and medicine for treating cerebral edema - Google Patents
Traditional Chinese medicine composition and medicine for treating cerebral edema Download PDFInfo
- Publication number
- CN116966247B CN116966247B CN202310514027.1A CN202310514027A CN116966247B CN 116966247 B CN116966247 B CN 116966247B CN 202310514027 A CN202310514027 A CN 202310514027A CN 116966247 B CN116966247 B CN 116966247B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- cerebral edema
- vinegar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 206010048962 Brain oedema Diseases 0.000 title claims abstract description 66
- 208000006752 brain edema Diseases 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 25
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 23
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940116229 borneol Drugs 0.000 claims abstract description 23
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 13
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 13
- 235000020224 almond Nutrition 0.000 claims abstract description 13
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 12
- 241000701408 Euphorbia kansui Species 0.000 claims abstract description 12
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims abstract description 12
- 235000006463 Brassica alba Nutrition 0.000 claims abstract description 11
- 244000140786 Brassica hirta Species 0.000 claims abstract description 11
- 235000011371 Brassica hirta Nutrition 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 241000241550 Cyathula Species 0.000 claims abstract description 10
- 241000218671 Ephedra Species 0.000 claims abstract description 10
- 241000434018 Euphorbia pekinensis Species 0.000 claims abstract description 9
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 8
- 229940010454 licorice Drugs 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 240000007890 Leonurus cardiaca Species 0.000 claims abstract 4
- 238000011282 treatment Methods 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 21
- 241001598107 Imperata Species 0.000 claims description 14
- 239000006187 pill Substances 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 235000021419 vinegar Nutrition 0.000 claims description 10
- 239000000052 vinegar Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 241000220261 Sinapis Species 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 21
- 230000002490 cerebral effect Effects 0.000 abstract description 12
- 206010022773 Intracranial pressure increased Diseases 0.000 abstract description 6
- 210000005036 nerve Anatomy 0.000 abstract description 6
- 201000009941 intracranial hypertension Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 206010014599 encephalitis Diseases 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 208000006011 Stroke Diseases 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 240000007171 Imperata cylindrica Species 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 20
- 230000001939 inductive effect Effects 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 14
- 208000004880 Polyuria Diseases 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 230000035619 diuresis Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 241000207925 Leonurus Species 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000003204 osmotic effect Effects 0.000 description 6
- 238000007917 intracranial administration Methods 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000002403 Encephalocele Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating cerebral edema, which is prepared from the following raw materials in parts by weight: 0.03-0.06 part of musk, 0.03-0.1 part of borneol, 1-3 parts of vinegar-baked euphorbia kansui, 1-3 parts of vinegar-baked euphorbia pekinensis, 1-3 parts of white mustard seed, 10-15 parts of cogongrass rhizome, 3-6 parts of amber, 10-15 parts of motherwort, 10-15 parts of medicinal cyathula root, 15-20 parts of poria cocos, 6-10 parts of ephedra herb, 10-12 parts of almond and 5-10 parts of baked licorice. The traditional Chinese medicine composition can effectively relieve common pathological mechanism-cerebral edema of diseases such as stroke, cerebral trauma and encephalitis, can relieve cerebral edema, reduce intracranial hypertension, improve nerve function and reduce death rate, has no obvious side effect and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and a medicine for treating cerebral edema.
Background
Cerebral edema is a nonspecific pathological swelling of the brain, and any type of nerve injury may develop gradually in a focal or diffuse manner, such as cerebral infarction, cerebral hemorrhage, encephalitis, brain tumor, hepatic encephalopathy, traumatic brain injury, etc. Commonly accepted cerebral oedema is defined as: the excessive accumulation of cerebral parenchymal fluid caused by various intracranial lesions and systemic diseases leads to increased brain volume and weight, and is classified into angiogenic cerebral edema, cytotoxic cerebral edema, interstitial cerebral edema and osmotic cerebral edema according to the pathogenesis and pathological changes. The development and progression of cerebral edema is a key factor in the deterioration of the patient's condition. In the early stages of cerebral edema formation, the patient's symptoms are mild and compensatory adjustments can be made in the brain, such as balancing the increase in water in the brain by reducing cerebrospinal fluid and blood volume. However, if the water content increases sharply due to the presence of the skull, cerebral edema progresses more rapidly than the maximum extent that can be compensated, resulting in increased intracranial pressure, eventually forming a cerebral hernia, causing damage to brain tissue and even leading to death of the patient. Cerebral edema is a powerful predictor of prognosis, accounting for 50% of mortality from severe traumatic brain injury, 80% of mortality from large-area cerebral infarction, and one third of hepatic encephalopathy patients die from cerebral edema and cerebral hemorrhage with consequent rise in intracranial pressure.
Cerebral edema belongs to critical clinical symptoms, and how to control the progress of cerebral edema in time is particularly critical for patients to get the golden opportunity for rescue. Current strategies for treating cerebral edema have not progressed as rapidly as other areas of the nervous system. The common method for controlling cerebral edema in modern medicine is surgical bone flap decompression, which can reduce mortality, but is limited in application by reasons such as increased long-term severe disability rate, critical illness, incapability of implementing patients with life-threatening complications, and the like. In addition, the recent emerging cryotherapy may improve neurological prognosis for controlling cerebral edema, but lacks central, large-sample clinical study support, and has a higher risk of adverse events during treatment. The application of osmotic therapy in the clinical treatment of cerebral edema is wide, however, the effectiveness thereof mainly depends on whether the blood-brain barrier is complete, the reflection coefficient of osmotic drugs and whether osmotic gradients are generated, and contraindications and adverse reactions exist in the use of such drugs, such as mannitol can cause hypovolemia and kidney injury, and hypertonic saline can cause ion metabolic disorder, volume overload, phlebitis, hypertension and the like. Other treatments such as analgesia sedation, elevation of bedside 30 °, hyperventilation, and the lack of high quality studies of the novel targeted drugs glibenclamide, bumetanide, fingolimod, etc. confirm their effectiveness.
The traditional Chinese medicine does not directly record and know 'cerebral edema', and according to symptoms after brain injury and pathophysiology of modern medicine, the modern traditional Chinese medicine proposes that the formation of cerebral edema is mostly caused by qi movement disorder, unsmooth blood circulation in brain and abnormal body fluid distribution, so that the cerebral vessels are overflowed with water; or qi deficiency and blood stasis in brain, unsmooth blood circulation and unfavorable distribution of body fluids; or overstrain, improper diet, long-term wetland, spleen deficiency and dampness stagnation, which can cause excessive water dampness and cover brain orifices; or qi and blood dysfunction, which results in stagnant blood in brain vessels or blood overflows to the brain, finally stagnant blood stays in the brain, water and fluid seeps out, and water stasis is mutually accumulated in the brain. The academic world of traditional Chinese medicine mainly expands some discussions around the pathogenesis typing of cerebral edema and the independent prescription of the pathogenesis typing of cerebral edema, but no traditional Chinese medicine preparation specially aiming at cerebral edema is marketed yet, and no significant breakthrough in clinical treatment, theory and the like can be generated.
Disclosure of Invention
Based on the above, the invention aims to provide a traditional Chinese medicine composition for treating cerebral edema, which can effectively relieve cerebral edema, reduce intracranial hypertension, improve nerve function and reduce the death rate.
In order to achieve the above purpose, the present invention adopts the following technical scheme.
The traditional Chinese medicine composition for treating cerebral edema is prepared from the following raw materials in parts by weight: 0.03-0.06 part of musk, 0.03-0.1 part of borneol, 1-3 parts of vinegar-baked euphorbia kansui, 1-3 parts of vinegar-baked euphorbia pekinensis, 1-3 parts of white mustard seed, 10-15 parts of cogongrass rhizome, 3-6 parts of amber, 10-15 parts of motherwort, 10-15 parts of medicinal cyathula root, 15-20 parts of poria cocos, 6-10 parts of ephedra herb, 10-12 parts of almond and 5-10 parts of baked licorice.
In some preferred embodiments, the active ingredients of the traditional Chinese medicine composition for treating cerebral edema are prepared from the following raw materials in parts by weight: 0.03-0.05 part of musk, 0.05-0.1 part of borneol, 1-3 parts of vinegar-baked euphorbia kansui, 1-3 parts of vinegar-baked euphorbia pekinensis, 1-3 parts of white mustard seed, 12-15 parts of cogongrass rhizome, 3-5 parts of amber, 12-15 parts of motherwort, 10-12 parts of medicinal cyathula root, 15-18 parts of poria cocos, 8-10 parts of ephedra herb, 10-12 parts of almond and 5-8 parts of baked licorice.
More preferably, the active ingredients of the traditional Chinese medicine composition for treating cerebral edema are prepared from the following raw materials in parts by weight: musk 0.03, borneol 0.1, vinegar-baked euphorbia kansui 3, vinegar-baked euphorbia pekinensis 3, white mustard seed 3, cogongrass rhizome 15, amber 3, motherwort 15, medicinal cyathula root 10, poria cocos 15, ephedra 8, almond 10 and baked licorice 5.
In some embodiments, the musk is an artificial musk.
The invention also provides a traditional Chinese medicine preparation for treating cerebral edema, which comprises the traditional Chinese medicine composition.
In some embodiments, the dosage form of the traditional Chinese medicine preparation is honeyed pills, granules, tablets, powder and capsules.
In some preferred embodiments, the dosage form of the traditional Chinese medicine preparation is a honeyed pill.
In some embodiments, the method for preparing the traditional Chinese medicine preparation comprises the following steps: (1) Pulverizing radix kansui Preparata with vinegar, semen Sinapis Albae, lalang grass rhizome, succinum, herba Leonuri, radix Cyathulae, poria, herba Ephedrae, semen Armeniacae amarum, radix Glycyrrhizae Preparata and radix Knoxiae Preparata with vinegar, and sterilizing; (2) Grinding musk and borneol, and then adding the ground musk and borneol into the sterilized product in the step (1) to obtain medicinal powder; (3) Adding refined honey into the medicinal powder, and making into pill to obtain the Chinese medicinal preparation.
In some embodiments, the weight ratio of the powder to refined honey is 1: (1-1.5).
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: (1) Pulverizing radix kansui Preparata with vinegar, semen Sinapis Albae, lalang grass rhizome, succinum, herba Leonuri, radix Cyathulae, poria, herba Ephedrae, semen Armeniacae amarum, radix Glycyrrhizae Preparata and radix Knoxiae Preparata with vinegar, and sterilizing; (2) Grinding musk and borneol, and then adding the ground musk and borneol into the sterilized product obtained in the step (1) to obtain the traditional Chinese medicine composition.
The invention also provides application of the traditional Chinese medicine composition in preparing a traditional Chinese medicine preparation for treating cerebral edema.
The invention provides a traditional Chinese medicine composition for treating cerebral edema, which comprises musk, borneol, vinegar-baked kansui root, white mustard seed, cogongrass rhizome, amber, motherwort, medicinal cyathula root, poria cocos, ephedra, almond, baked licorice root and vinegar-baked euphorbia pekinensis. The traditional Chinese medicine composition mainly comprises 'son Long Miao pills' and 'Cantonese decoction', and is composed of drugs for inducing resuscitation and restoring consciousness and promoting blood circulation and inducing diuresis, and has the effects of 'drastic draining water, promoting blood circulation and removing blood stasis, restoring consciousness and restoring spirit'. Wherein, the 'ZI Long Miao Yingwan' is taken as a monarch drug: white mustard seed is taken to enter the lung to reach upper jiao, vinegar-baked euphorbia kansui is yellow to enter the spleen to move middle jiao, vinegar-baked euphorbia kansui is black to enter the kidney to move lower jiao, white mustard seed is taken to move water decoction outside the inner membrane of the skin, euphorbia kansui is taken to move through tunnel water decoction, vinegar-baked euphorbia kansui is taken to move through viscera, and the three are led to be different, so that water is removed under drastic action, and cerebral edema is eliminated from urination and defecation. The ministerial drugs comprise motherwort herb and cogongrass rhizome, which can promote blood circulation and induce diuresis, and can promote the brain to open, and can promote the water passage to remove blood stasis and promote tissue regeneration; succinum has effects of promoting blood circulation for removing blood stasis, inducing diuresis for treating stranguria, and can induce pathogenic factors to descend; radix Cyathulae has effects of inducing fire and descending blood, promoting blood circulation and removing water retention, and tonifying liver and kidney. With the assistance of 'Cannabis decoction', the ephedra can ventilate the lung and the boiled water can be added into the lung to ventilate the souls; the almond enters collaterals to reduce the adverse flow of the almond; prepared licorice root, radix Glycyrrhizae Praeparata goes into the fu organs to slow down its sudden and violent adverse reaction to dissipate the power and to tranquilize the mind. The medicine is musk, fragrant and pungent in smell, good in dredging the orifices, and small in dosage, the medicine is used for inducing resuscitation, promoting blood circulation, promoting diuresis, ascending the clear and descending the turbid; borneol has aromatic effect for inducing resuscitation.
The inventor has clinical research experience of treating various cerebral oedemas by years of engaged in traditional Chinese medicine, combines modern pharmacological research results, is based on the theory of 'cerebral water stasis', combines clinical practice, and can quickly and effectively reduce cerebral oedema and intracranial pressure by continuously optimizing a formula, thereby improving nerve function, reducing death rate, having no obvious side effect and having wide application prospect.
Drawings
FIG. 1 is a graph showing the results of a 3 month mRS patient ratio analysis for the treatment group and the control group.
Detailed Description
The experimental methods of the present invention, in which specific conditions are not specified in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. The various chemicals commonly used in the examples are commercially available.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The terms "comprising" and "having" and any variations thereof, are intended to cover a non-exclusive inclusion. For example, a process, method, apparatus, article, or device that comprises a list of steps is not limited to the elements or modules listed but may alternatively include additional steps not listed or inherent to such process, method, article, or device.
Cerebral edema is a neurologic emergency, and is a peak of cerebral edema 3-5 days after acute brain injury, and if the cerebral edema is not cured in time, the cerebral edema becomes herniated, so that coma and respiratory heartbeat stop are caused. Modern traditional Chinese medicine holds that the 'water stasis inter-junction intracranial' caused by various causes is a core pathogenesis of cerebral edema, and blood stasis and water drink are mutually influenced and mutually cemented, so that brain spirit is malnourished, and brain orifices are not led to be led to the communication. The brain is the house of the spirit, the place of the spirit of people and the place of clearing the orifices, and the precious place of clearing the smart. The inventor combines abundant clinical experience and a large amount of basic research results, and considers that the treatment of cerebral edema is critical in removing the evil of cerebral water stasis as soon as possible, and the medicine can be directly introduced into brain orifices to break malignant circulation so as to recover qing ling. In the treatment of the symptom of cerebral water stasis, the single treatment of the symptom of cerebral water stasis is that the water is not removed, the water is not dispersed, the orifice is not communicated, and the treatment of the symptom of the cerebral water stasis is that only the symptom of removing the water stasis and inducing diuresis, and the restoration of consciousness are positive. Therefore, the medicine prescription with great special effect and quick effect can relieve the danger, the medicine with drastic water-expelling effect can rapidly discharge excessive water in brain tissues in a short period, and simultaneously does not forget to remove blood stasis and detoxify, open brain orifices, and has no toxic or side effect on human bodies, so that the traditional Chinese medicine composition is continuously optimized and obtained on the basis.
The following description is made with reference to specific embodiments.
Example 1
The embodiment provides a traditional Chinese medicine composition for treating cerebral edema, which is prepared from the following raw materials in parts by weight: musk 0.03, borneol 0.1, vinegar-baked euphorbia kansui 3, vinegar-baked euphorbia pekinensis 3, white mustard seed 3, cogongrass rhizome 15, amber 3, motherwort 15, medicinal cyathula root 10, poria cocos 15, ephedra 8, almond 10 and baked licorice 5.
The invention also provides a traditional Chinese medicine preparation for treating cerebral edema, which is a honeyed pill, and the preparation method comprises the following steps: (1) Pulverizing radix kansui Preparata with vinegar, semen Sinapis Albae, lalang grass rhizome, succinum, herba Leonuri, radix Cyathulae, poria, herba Ephedrae, semen Armeniacae amarum, radix Glycyrrhizae Preparata and radix Knoxiae Preparata with vinegar, and sterilizing; (2) Grinding artificial musk, crushing borneol, and then adding the crushed musk into the sterilized product in the step (1) to obtain medicinal powder; (3) Adding 100-150 g refined honey (medium honey) into 100g of the medicinal powder, and making into big honeyed pill with 9 g pill weight.
Example 2
This example uses the honeyed pill of example 1 to treat patients with cerebral infarction and cerebral edema.
The clinical efficacy and safety of the honeyed pill described in example 1 in treating large area cerebral infarction were observed by prospective, randomized controlled, blind endpoint study.
The key points of syndrome differentiation are as follows: (1) the blindness is manifested by distending head, headache, excessive phlegm and saliva, dizziness, emesis, absentmindedness, amnesia, insomnia, or even confusion, dull expression, and slow reaction. Or epilepsy and convulsion; the people can cry and laugh, lose the calculation and act strangely; or see language reversal, word shortages, etc. (2) The loss of the limbs manifests as numbness, swelling, heavy stagnation, weakness, and muscle and tendon loss . Or hand and foot shake, or limb disuse, or even hemiplegia. (3) Loss of seven orifices is manifested as slurred speech, even loss of speech, stiff tongue root, choking and cough with drinking water, excessive mouth and saliva, excessive eyes and tears, excessive nose and nasal discharge, blurred vision or blurred vision, facial distortion, tinnitus and deafness, and incontinence of urination and urination. (4) The tongue pulse is manifested as a plurality of reddish or purple or bluish-purple tongue; the tongue body has blood stasis points and blood stasis spots, or the tongue body is fat and has tooth marks; coarse and dark color of sublingual venation; the tongue coating is watery or greasy. Its pulse condition is usually wiry and slippery, wiry and hard or deep, thready and astringent.
Patients were enrolled in 60 cases and randomized into 2 groups (treatment and control) of 30 cases each. Wherein, the honeyed pill described in example 1 is added to the Western basic treatment scheme, and the dosage is as follows: 9 g each time, twice daily, and nasal feeding after warming and melting; the control group used only the western medicine basal treatment regimen. The western medicine base treatment regimen was performed with reference to the on-screen large area cerebral infarction (Large hemispheric infarction, LHI) guidelines issued together on Neurocrit Care by the national institute of neurological intensive Care and emergency medical society (NCS).
The relevant efficacy index and laboratory data index at day 4, day 7, day 14 and month 3 after treatment were analyzed separately, the comparison between the two groups of the normal distribution was made using the independent sample T test for the metric data, the comparison between the two groups of the normal distribution was made using the mann-whitty rank sum test for the non-compliance, and the comparison between the count data groups was made using the X2 test, with P <0.05 being considered statistically different. The results are shown in Table 1:
TABLE 1 analysis of efficacy
Complications and bowel movements of both groups of patients during treatment are shown in table 2:
TABLE 2 complications and bowel movement conditions for two groups of patients
| Project | Treatment group (n=30) | Control group (n=30) | P |
| Complications of the invention | |||
| Bleeding conversion [ n (%)] | 6(20.0) | 3(10.0) | 0.278 |
| Epilepsy [ n (%)] | 2(6.7) | 2(6.67) | 1.000 |
| Venous thrombosis [ n (%)] | 3(10.0) | 6(20.0) | 0.278 |
| Acute heart failure [ n (%)] | 0(0.0) | 1(3.3) | 0.313 |
| Pneumonia [ n (%)] | 18(60.0) | 18(60.0) | 1.000 |
| Constipation of stool | |||
| Diarrhea [ n (%)] | 8(26.7) | 3(10.0) | 0.068 |
| Average number of stool/day M [ IQR ]] | 0.75(0.6-1.3) | 0.5(0.3-0.7) | 0.001* |
The results of the 3 month mRS patient ratio analysis for the treatment and control groups are shown in figure 1. Mortality in the treatment and control groups was 26.7% (8/30) and 53.3% (16/30) at 3 months, respectively; the severe disability rate of surviving patients was 36.4% (8/22) and 64.3% (9/14), respectively; the median severe disability rate in surviving patients was 86.4% (19/22) and 92.9% (13/14), respectively; the prognosis is good (mRS.ltoreq.3 min.) at 16.6% (5/30) and 3.3% (1/30), respectively. Mortality in the treatment group was significantly reduced, statistically significant (p=0.035).
The results show that the traditional Chinese medicine composition provided by the invention is safe for treating large-area cerebral infarction, and can reduce mortality (the death rate of a treatment group and a control group is respectively 26.7% and 53.3%, and P is less than 0.05), and cerebral edema (the midline shift of a skull CT display is carried out for 7 days, and the death rate of the treatment group is obviously lower than that of the control group, and P is less than 0.05). The secondary outcome measures were further analyzed, NIHSS score at day 7, central line shift shown by cranium CT was significantly lower in the treatment group than in the control group, blood osmolarity level at day 7 was significantly higher than in the control group (P < 0.05), and stool average number/day was significantly greater than in the control group (P < 0.05).
We analyze that the mechanism by which the Chinese medicinal composition of the present invention acts may be: by relieving cerebral edema, the nerve function of the patient is improved, and the death rate of large-area cerebral infarction is reduced. The cerebral edema of large-area cerebral infarction usually rapidly progresses to peak within 5 days of onset, patients within 48 hours of onset are involved, and the early intervention by using the traditional Chinese medicine composition also shows that the NIHSS score on the 7 th day of a treatment group and the midline shift of the skull CT display are obviously lower than those of a control group, so that the cerebral edema can be relieved after the traditional Chinese medicine is dried. The blood osmotic pressure level on the 7 th day is obviously higher than that of a control group, and the average number of times of stool during treatment is obviously increased, so that the traditional Chinese medicine composition can achieve the effect similar to that of osmotic therapy by promoting diuresis and reducing turbidity, so as to relieve cerebral edema, alleviate intracranial hypertension and improve nerve function.
In previous studies, the inventors have created other formulations for treating cerebral oedema, such as a formulation with better efficacy: 15-30g of red sage root, 15-30g of motherwort herb, 10-12g of szechuan lovage rhizome, 10-15g of red paeony root, 10-15g of peach seed, safflower and medicinal cyathula root, 15-24g of Indian buead, 0.1-0.2g of musk (taken after being infused with water) and 6-10g of amber. When musk is absent, 10-12g of angelica dahurica or 0.1-0.2g of borneol can be used for replacing (taking with water). In the recipe, musk and borneol are prepared by dissolving decoction for inducing resuscitation and activating blood, and musk and borneol are fragrant in smell, induce resuscitation and activating blood, induce yin to reach yang, and fragrance to channel away, so the recipe is suitable for treating hydrocephalus and blood accumulation, and is a monarch drug; chuan Xiong is pungent and warm in nature and moves away, moves qi and activates blood, is a qi-flowing herb in blood, and is combined with she Xiang to increase its action of inducing resuscitation; the salvia miltiorrhiza has the same function as four substances, and is used for activating blood and dissolving stasis without hurting the healthy energy; peach kernel and safflower activate blood and remove stasis; the red paeony root has the effects of promoting qi and blood circulation and strengthening the blood stasis and is taken as a ministerial drug; motherwort herb and tuckahoe, herba Leonuri and tuckahoe, poria have the effect of promoting blood circulation and removing water retention, and can be used for inducing resuscitation and water retention to help remove blood stasis and promote tissue regeneration; radix Cyathulae has effects of inducing fire and descending blood, promoting blood circulation and promoting diuresis, tonifying liver and kidney, promoting diuresis and relieving constipation, and semen Persicae has effects of loosening bowel and relieving constipation, and can be used as adjuvant drug for eliminating pathogenic factors from the front and back of the patient; succinum has effects of promoting blood circulation for removing blood stasis, inducing diuresis for treating stranguria, and can induce pathogenic factors to act downwards to treat severe cerebral edema, and often has effects of dewatering and lowering intracranial pressure. However, in clinical practice, the prescription has the important effects of activating blood and removing stasis, inducing resuscitation and dredging collaterals, but has insufficient blood-activating and diuresis-promoting effects, and from the modern medical point of view, "cerebral edema-intracranial hypertension-cerebral hernia-central respiratory circulatory failure" is a pathological process of worsening of the condition. The key point of the treatment is that the pathogenic factor of the craniocerebral water stasis is removed as soon as possible, and the medicine can be directly introduced into brain orifices to break the malignant circulation so as to recover the qingling. In the treatment of the symptom of cerebral water stasis, the single treatment of the symptom of cerebral water stasis is that the water is not removed, the water is not dispersed, the orifice is not communicated, and the treatment of the symptom of the cerebral water stasis is that only the symptom of removing the water stasis and inducing diuresis, and the restoration of consciousness are positive. Therefore, the medicine has the advantages of great special effect, quick response, capability of draining excessive water of brain tissues in a short period to eliminate edema, no forgetting to remove blood stasis and detoxify, opening brain orifices, and no toxic or side effect on human bodies. Based on the above formula, the Zilong Miao pill is added to remove water and eliminate phlegm, so that the craniocerebral water evil can go out from the urination and defecation, and the effect of promoting diuresis is enhanced; adding herba Ephedrae into lung to make it calm; the almond enters collaterals to reduce the adverse flow of the almond; prepared licorice root, radix Glycyrrhizae Praeparata goes into the fu organs to slow down its sudden and violent, will be dispersed in the adverse reaction and soul will be enough to assist musk and borneol to refresh the brain and induce resuscitation. Thus, the defects of the above formula are overcome, the treatment effect is further improved, and the mortality and disability rate are reduced.
In conclusion, the traditional Chinese medicine composition disclosed by the invention can effectively relieve common pathological mechanisms of diseases such as stroke, cerebral trauma and encephalitis, namely cerebral edema, relieve cerebral edema, reduce intracranial hypertension, improve nerve function and reduce death rate, and has a wide application prospect.
The technical features of the above embodiments may be arbitrarily combined, and all possible combinations of the technical features in the above embodiments are not described for brevity of description, however, as long as there is no contradiction between the combinations of the technical features, they should be considered as the scope of the description.
The foregoing examples illustrate only a few embodiments of the invention and are described in detail herein without thereby limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (10)
1. The traditional Chinese medicine composition for treating cerebral edema is characterized in that the active ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in parts by weight: 0.03-0.06 part of musk, 0.03-0.1 part of borneol, 1-3 parts of vinegar-baked euphorbia kansui, 1-3 parts of vinegar-baked euphorbia pekinensis, 1-3 parts of white mustard seed, 10-15 parts of cogongrass rhizome, 3-6 parts of amber, 10-15 parts of motherwort, 10-15 parts of medicinal cyathula root, 15-20 parts of poria cocos, 6-10 parts of ephedra herb, 10-12 parts of almond and 5-10 parts of baked licorice.
2. The traditional Chinese medicine composition for treating cerebral edema according to claim 1, wherein the active ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in parts by weight: 0.03-0.05 part of musk, 0.05-0.1 part of borneol, 1-3 parts of vinegar-baked euphorbia kansui, 1-3 parts of vinegar-baked euphorbia pekinensis, 1-3 parts of white mustard seed, 12-15 parts of cogongrass rhizome, 3-5 parts of amber, 12-15 parts of motherwort, 10-12 parts of medicinal cyathula root, 15-18 parts of poria cocos, 8-10 parts of ephedra herb, 10-12 parts of almond and 5-8 parts of baked licorice.
3. The traditional Chinese medicine composition for treating cerebral edema according to claim 1, wherein the active ingredients of the traditional Chinese medicine composition are prepared from the following raw materials in parts by weight: musk 0.03, borneol 0.1, vinegar-baked euphorbia kansui 3, vinegar-baked euphorbia pekinensis 3, white mustard seed 3, cogongrass rhizome 15, amber 3, motherwort 15, medicinal cyathula root 10, poria cocos 15, ephedra 8, almond 10 and baked licorice 5.
4. A traditional Chinese medicine preparation for treating cerebral edema, characterized in that the active ingredient of the traditional Chinese medicine preparation is the traditional Chinese medicine composition according to any one of claims 1-3.
5. The traditional Chinese medicine preparation for treating cerebral edema according to claim 4, wherein the dosage form of the traditional Chinese medicine preparation is honeyed pills, granules, tablets, powder and capsules.
6. The traditional Chinese medicine preparation for treating cerebral edema according to claim 5, wherein the dosage form of the traditional Chinese medicine preparation is a honeyed pill.
7. The method for preparing a traditional Chinese medicine preparation for treating cerebral edema according to claim 6, comprising the following steps: (1) Pulverizing radix kansui Preparata with vinegar, semen Sinapis Albae, lalang grass rhizome, succinum, herba Leonuri, radix Cyathulae, poria, herba Ephedrae, semen Armeniacae amarum, radix Glycyrrhizae Preparata and radix Knoxiae Preparata with vinegar, and sterilizing; (2) Grinding musk and borneol, and then adding the ground musk and borneol into the sterilized product in the step (1) to obtain medicinal powder; (3) Adding refined honey into the medicinal powder, and making into pill to obtain the Chinese medicinal preparation.
8. The method for preparing a traditional Chinese medicine preparation for treating cerebral edema according to claim 7, wherein the weight ratio of the medicinal powder to refined honey is 1: (1-1.5).
9. A method for preparing a Chinese medicinal composition according to any one of claims 1 to 3, comprising the steps of: (1) Pulverizing radix kansui Preparata with vinegar, semen Sinapis Albae, lalang grass rhizome, succinum, herba Leonuri, radix Cyathulae, poria, herba Ephedrae, semen Armeniacae amarum, radix Glycyrrhizae Preparata and radix Knoxiae Preparata with vinegar, and sterilizing; (2) Grinding musk and borneol, and then adding the ground musk and borneol into the sterilized product obtained in the step (1) to obtain the traditional Chinese medicine composition.
10. Use of a Chinese medicinal composition according to any one of claims 1 to 3 for the preparation of a Chinese medicinal preparation for the treatment of cerebral oedema.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023100975941 | 2023-02-07 | ||
| CN202310097594.1A CN116036200A (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition and medicine for treating cerebral edema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116966247A CN116966247A (en) | 2023-10-31 |
| CN116966247B true CN116966247B (en) | 2024-03-22 |
Family
ID=86116376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310097594.1A Pending CN116036200A (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition and medicine for treating cerebral edema |
| CN202310514027.1A Active CN116966247B (en) | 2023-02-07 | 2023-05-08 | Traditional Chinese medicine composition and medicine for treating cerebral edema |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310097594.1A Pending CN116036200A (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition and medicine for treating cerebral edema |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116036200A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1994411A (en) * | 2006-12-20 | 2007-07-11 | 丁金良 | Medicine for treating cerebral apoplexy |
| CN101279016A (en) * | 2008-05-29 | 2008-10-08 | 赵青菊 | Oral medicament for curing craniocerebral injury associated with hydrocephalus |
| CN101919944A (en) * | 2010-08-02 | 2010-12-22 | 靳照礼 | Traditional Chinese medicine compound, preparation method and application thereof |
-
2023
- 2023-02-07 CN CN202310097594.1A patent/CN116036200A/en active Pending
- 2023-05-08 CN CN202310514027.1A patent/CN116966247B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1994411A (en) * | 2006-12-20 | 2007-07-11 | 丁金良 | Medicine for treating cerebral apoplexy |
| CN101279016A (en) * | 2008-05-29 | 2008-10-08 | 赵青菊 | Oral medicament for curing craniocerebral injury associated with hydrocephalus |
| CN101919944A (en) * | 2010-08-02 | 2010-12-22 | 靳照礼 | Traditional Chinese medicine compound, preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| "治血四法"理论在颅脑损伤中的应用;王健;周晓燕;;中国中医急症;20141215(第12期);第2381-2382页 * |
| 中医关于脑出血后脑水肿的新认识和新发展;张梦雪;全咏华;周德生;;中医药学报;20191231(第06期);第5-9页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116966247A (en) | 2023-10-31 |
| CN116036200A (en) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101559195B (en) | Epilepsy therapy capsule and preparation method thereof | |
| CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
| CN103768283A (en) | Traditional Chinese medicine for treating multiple eye diseases | |
| CN100586458C (en) | Medicine for treating cerebral apoplexy | |
| CN106334107A (en) | Traditional Chinese medicine eye drops and preparation method thereof | |
| CN115414407B (en) | Zhuang medicine compound medicine for treating ischemic cerebral apoplexy and preparation method thereof | |
| CN116966247B (en) | Traditional Chinese medicine composition and medicine for treating cerebral edema | |
| CN108126160B (en) | Traditional Chinese medicine composition, traditional Chinese medicine health tea, preparation method and application thereof | |
| CN103127466B (en) | Chinese medicine decoction for treating cognitive disorder of Parkinson disease | |
| CN114010751B9 (en) | Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue | |
| CN112741890B (en) | Traditional Chinese medicine composition for treating vertigo and preparation method thereof | |
| CN111888449B (en) | Traditional Chinese medicine composition for treating Parkinson's depression disease and application thereof | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN1256145C (en) | External use sticking-plaster for treating peripheral prosopoplegia | |
| CN107080786A (en) | Antidepressant compositions and its preparation method and application and medicine or pharmaceutical composition comprising it | |
| CN100370973C (en) | Traditional Chinese medicinal prepn. for treating obstruction of qi in the chest | |
| CN103638388A (en) | Traditional Chinese medicine composition for treating chloasma, preparation and preparation method thereof | |
| CN101024042A (en) | Medicine preparation for treating rheumatism disease by jointing Chinese medicine and western medicine | |
| CN1081888A (en) | Treatment commonly encountered diseases of internal department, the apoplexy of frequently-occurring disease and the Chinese patent medicine tablet of sequela | |
| CN107184916B (en) | Traditional Chinese medicine composition with depression treatment effect, preparation method and application | |
| CN104547619A (en) | Traditional Chinese medicine for treating apoplexy sequela paralytic limbs and preparation method of traditional Chinese medicine | |
| CN100542599C (en) | Glaucomatous medicine of a kind of treatment and preparation method thereof | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN104042769A (en) | Medicinal composition for treating prosopalgia | |
| CN116019891B (en) | Traditional Chinese medicine ointment formula for treating tinnitus and deafness and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |